Psoriatic Arthritis Treatment Market Forecast and Opportunities 2024-2032
The Psoriatic Arthritis Treatment Market was valued at USD 11.08 billion in 2023 and is expected to reach USD 25.41 billion by 2032, growing at a CAGR of 9.70% from 2024-2032.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/3223
Regional Analysis
The market exhibits significant regional variations:
- North America: Dominates the market due to advanced healthcare infrastructure and high awareness levels.
- Europe: Holds a substantial share, attributed to supportive government initiatives and widespread adoption of biologic therapies.
- Asia-Pacific: Anticipated to experience rapid growth, driven by increasing healthcare investments and rising disease awareness.
Market Segmentation
The market is segmented based on:
- Drug Class:
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Disease-Modifying Antirheumatic Drugs (DMARDs)
- Biologics
- Others
- Route of Administration:
- Topical
- Oral
- Injectable
- Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Some of the major key players in the Psoriatic Arthritis Treatment Market
- AbbVie (Humira, Rinvoq)
- Amgen (Enbrel, Aimovig)
- Johnson & Johnson (Stelara, Tremfya)
- Novartis (Cosentyx, Kisqali)
- Merck & Co. (Remicade, Jemperli)
- Pfizer (Xeljanz, Enbrel)
- Bristol-Myers Squibb (Orencia, Otezla)
- Eli Lilly and Company (Taltz, Olumiant)
- Sanofi (Kevzara, Dupixent)
- Gilead Sciences (Biktarvy, Veklury)
- UCB Pharma (Cimzia, Kusabri)
- Abbott Laboratories (Humira, Simulect)
- Horizon Therapeutics (Tepezza, Krystexxa)
- Boehringer Ingelheim (Olumiant, Actemra)
- Roche (Actemra, Venclexta)
- Celltrion Healthcare (Remsima, Truxima)
- Mylan (Renflexis, Biosimilars in Development)
- Teva Pharmaceutical Industries (Copaxone, Ajovy)
- Samsung Biologics (Renflexis, Biosimilars Pipeline)
- AstraZeneca (Fasenra, Imfinzi)
Key Points
- Increasing global prevalence of psoriatic arthritis.
- Advancements in biologic treatments offering improved management options.
- Growing awareness leading to early diagnosis and timely treatment.
- Expanding pipeline of novel therapies enhancing treatment options.
Future Scope
The Psoriatic Arthritis Treatment Market is poised for substantial growth, driven by continuous advancements in therapeutic options and increasing awareness. The focus on personalized medicine and targeted biologic therapies is expected to enhance patient outcomes. Emerging markets, particularly in the Asia-Pacific region, present significant opportunities due to improving healthcare infrastructure and rising disease awareness. Ongoing research and development efforts are anticipated to introduce innovative treatments, further propelling market expansion.
Conclusion
The Psoriatic Arthritis Treatment Market is on a robust growth trajectory, supported by technological advancements, heightened awareness, and a strong pipeline of novel therapies. Strategic collaborations and investments in research are expected to address unmet medical needs, offering improved quality of life for patients globally.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian